532 related articles for article (PubMed ID: 15734600)
1. The impact of a monophasic continuous estro-progestogenic treatment on Latin American menopausal women.
Bassol S; Carranza-Lira S; Celis-Gonzalez C; Santoyo S; Murillo A; Martinez N; Santos J; Llaca V; de la Loza FR; Zarain J; da Fonseca AM; Camargos AF; Baracat EC; da Sá MF; Bayo J; Adaro L; Gurucharri C; Murga M; Siseles N; Sayegh F; Tempone A; Tempone LM; Tozzini RI; Boccanera R; Naranjo C; Sanchez F; Gomez G; Blanco S; Reyes-Marquez R; Albrecht G; Rios PC
Maturitas; 2005 Mar; 50(3):189-95. PubMed ID: 15734600
[TBL] [Abstract][Full Text] [Related]
2. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
Rozenberg S; Ylikorkala O; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
[TBL] [Abstract][Full Text] [Related]
3. Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy.
Ylikorkala O; Lim P; Caubel P
Clin Ther; 2000 May; 22(5):622-36. PubMed ID: 10868559
[TBL] [Abstract][Full Text] [Related]
4. Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naïve Thai women.
Jirapinyo M; Theppisai U; Manonai J; Suchartwatnachai C; Jorgensen LN
Acta Obstet Gynecol Scand; 2003 Sep; 82(9):857-66. PubMed ID: 12911449
[TBL] [Abstract][Full Text] [Related]
5. The lipid and clinical effects of sequential transdermal estradiol and estradiol/norethisterone acetate in 674 women.
Cano A; Calaf J; Molina J
Arch Gynecol Obstet; 2003 Oct; 268(4):317-22. PubMed ID: 14504877
[TBL] [Abstract][Full Text] [Related]
6. One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women.
Samsioe G; Dvorak V; Genazzani AR; Hamann B; Heikkinen J; Mueck AO; Suzin J; Kawakami FT; Ferreira A; Sun D; Arguinzoniz M
Maturitas; 2007 Jun; 57(2):171-81. PubMed ID: 17317046
[TBL] [Abstract][Full Text] [Related]
7. The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women.
Arrenbrecht S; Caubel P; Garnero P; Felsenberg D
Maturitas; 2004 Jul; 48(3):197-207. PubMed ID: 15207885
[TBL] [Abstract][Full Text] [Related]
8. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability.
Hammar ML; van de Weijer P; Franke HR; Pornel B; von Mauw EM; Nijland EA;
BJOG; 2007 Dec; 114(12):1522-9. PubMed ID: 17995496
[TBL] [Abstract][Full Text] [Related]
9. [Effect of combined conjugated estrogen-medrogestone replacement therapy on lipid profiles, climacteric symptoms and the endometrium].
Belaisch J; Nappi C; Affinito P; De Gezelle H; Botelho M; Oliveira HM; Martinez-Oliveira J; Gonzaga F
J Gynecol Obstet Biol Reprod (Paris); 2000 Feb; 29(1):29-40. PubMed ID: 10675831
[TBL] [Abstract][Full Text] [Related]
10. Effects of postmenopausal hormone replacement therapy on body fat composition.
Yüksel H; Odabasi AR; Demircan S; Köseoğlu K; Kizilkaya K; Onur E
Gynecol Endocrinol; 2007 Feb; 23(2):99-104. PubMed ID: 17454160
[TBL] [Abstract][Full Text] [Related]
11. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
[TBL] [Abstract][Full Text] [Related]
12. Effects of oral continuous 17beta-estradiol plus norethisterone acetate replacement therapy on abdominal subcutaneous fat, serum leptin levels and body composition.
Yüksel H; Odabaşi AR; Demircan S; Karul A; Kozaci LD; Köseoğlu K; Kizilkaya K; Başak O
Gynecol Endocrinol; 2006 Jul; 22(7):381-7. PubMed ID: 16864148
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two forms of continuous combined hormone replacement therapy with respect to metabolic effects.
Tugrul S; Yildirim G; Pekin O; Uslu H; Kutlu T; Eren S
Arch Gynecol Obstet; 2007 May; 275(5):335-9. PubMed ID: 17051405
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe).
Nakajima ST; Archer DF; Ellman H
Contraception; 2007 Jan; 75(1):16-22. PubMed ID: 17161118
[TBL] [Abstract][Full Text] [Related]
15. Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding.
Yildirim G; Tugrul S; Uslu H; Pekin O; Eren S
Arch Gynecol Obstet; 2006 Feb; 273(5):268-73. PubMed ID: 16315025
[TBL] [Abstract][Full Text] [Related]
16. A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate.
Neven P; Lunde T; Benedetti-Panici P; Tiitinen A; Marinescu B; de Villiers T; Hillard T; Cano A; Peer E; Quail D; Nickelsen T;
BJOG; 2003 Feb; 110(2):157-67. PubMed ID: 12618160
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, multicentre study comparing the clinical effects of two sequential estradiol-progestin combinations containing either desogestrel or norethisterone acetate in climacteric women with estrogen deficiency symptoms.
Saure A; Hirvonen E; Milsom I; Christensen A; Damber MG
Maturitas; 1996 May; 24(1-2):111-8. PubMed ID: 8794442
[TBL] [Abstract][Full Text] [Related]
18. Effects of menopausal hormone therapy on hemostatic parameters, blood pressure, and body weight: open-label comparison of randomized treatment with estradiol plus drospirenone versus estradiol plus norethisterone acetate.
Junge W; El-Samalouti V; Gerlinger C; Schaefers M
Eur J Obstet Gynecol Reprod Biol; 2009 Dec; 147(2):195-200. PubMed ID: 19879683
[TBL] [Abstract][Full Text] [Related]
19. Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5 mg/NETA 0.1 mg.
Johansen OE; Qvigstad E
Adv Ther; 2008 Jun; 25(6):525-51. PubMed ID: 18568306
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy and safety of combined estradiol valerate and dienogest: a new no-bleed treatment.
von Schoultz B
Climacteric; 2003 Aug; 6 Suppl 2():24-32. PubMed ID: 14669841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]